Back to search

Article

Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – a case report

2024-01-02

Abstract excerpt

<title>Abstract</title> <p>The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable and self-determining after dose-reduction or termination of the drug. However, here we present a new aspect of BTKi’s that needs to be taken into consideration as we report two cases of life-threatening aplastic ane...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e45a179a-9965-5dd7-9dd6-c14fa00475f5
DOI
10.21203/rs.3.rs-3795875/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – a case reportDOI 10.21203/rs.3.rs-3795875/v1
Select a neighboring publication to make it the new centre.